Inhibikase Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.38
- 52-Week Range
- $1.36 – $2.61
- Market Cap
- $193.57M
- P/E (TTM)
- —
- EPS (TTM)
- -0.40
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.47
- PEG Ratio
- —
- Return on Equity
- -52.87%
- Return on Assets
- -33.76%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 15.34
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-24.46M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $83.84M
Market Snapshot
About
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing protein kinase inhibitors to modify the course of Parkinson's disease and related neurodegenerative disorders. The company's lead product candidate, IkT-148009, is designed to inhibit c-Abl, a protein kinase that has been implicated in the progression of Parkinson's disease by promoting the accumulation of toxic protein aggregates. Inhibikase is conducting clinical trials to evaluate IkT-148009's potential to slow or stop disease progression rather than just treating symptoms. The company represents a novel approach to addressing neurodegenerative diseases by targeting underlying disease mechanisms at the molecular level.